Segment Information

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Segment Information

22. Segment Information

The Company operates exclusively in the biotechnology sector. The Company’s business is considered as operating in one segment. The Company’s Chief Executive Officer is the chief operating decision maker and reviews the consolidated results of operations when making decisions about resources allocation and assessing performance of the Company as a whole. All revenues are generated from the subsidiaries located in China. Total long-lived assets of $208,618 including prepaid land lease payments, property, plant and equipment are all located in mainland China (December 31, 2019 - $82,275). The Company’s total assets by geographic location are as follows:

	December 31,
	2020		2019
Assets
Mainland China	$	1,824,380	$	384,297
Outside Mainland China		76,946		68,002
Total Assets	$	1,901,326	$	452,299

The Company’s revenues by market type are as follows:

	For the year ended December 31,
	2020		2019		2018
Sales
EPI	$	96,799	$	6,896	$	10,357
Private Pay		268,821		220,217		204,764
Export		145,004		18,940		14,529
Total Sales	$	510,624	$	246,053	$	229,650

The Company’s revenues are attributed to geographic locations as follows:

	For the year ended December 31,
	2020		2019		2018
Sales
Mainland China	$	365,620	$	227,113	$	215,121
Outside Mainland China		145,004		18,940		14,529
Total Sales	$	510,624	$	246,053	$	229,650